ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Protalix BioTherapeutics, Inc. (PLX) shows an Average True Range (ATR) of 0.08 and an Enterprise Value of 91.04M. Its average trading volume over the past 3 months is 1.04M, indicating liquidity. These fundamental metrics provide insight into PLX's underlying financial health and market activity.
Protalix BioTherapeutics, Inc. (PLX) technical indicators as of August 1, 2025: the SMA 20 is -1.88%, SMA 50 at -3.55%, and SMA 200 at -24.19%. The RSI 14 value is 45.52, suggesting its current momentum. These technical analysis signals help assess PLX's price trends and potential future movements.
Protalix BioTherapeutics, Inc. (PLX) stock performance overview as of August 1, 2025: The 52-week high is $3.1 (currently -52.9% below), and the 52-week low is $0.821 (currently 77.75% above). Over the past year, PLX's performance is 25.86%, compared to the S&P 500's 14.84% change.
According to market data, Protalix BioTherapeutics, Inc. (PLX) stock's recent performance metrics show that over the last month, PLX is -1.35%, with a Year-to-Date (YTD) performance of -22.34%. Over the past year, the stock has seen a 25.86% change. These figures summarize PLX's price movements across various periods, reflecting its historical returns.
According to current financial data, PLX stock's P/E (TTM) ratio is 29.41, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for PLX, including P/S (2.00), P/B (2.54), and P/FCF (-76.45), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.